Psychosocial Treatment of Depression in Parkinson's Disease
Primary Purpose
Major Depressive Disorder, Parkinson's Disease
Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Cognitive Behavioral Therapy
Cognitive Behavioral Therapy
Sponsored by
About this trial
This is an interventional treatment trial for Major Depressive Disorder focused on measuring Depression, Parkinson's Disease, Major Depression, Cognitive Behavioral Therapy
Eligibility Criteria
Inclusion Criteria:
In addition to the DSM-IV diagnostic criteria for major depressive disorder, the following conditions must be met for patient eligibility:
- Written informed consent.
- Subjects with a primary diagnosis of PD who also currently meet DSM-IV criteria for MDD
- Subjects must be stable on their anti-Parkinson treatment, as defined by no medication changes over the past 6 weeks
- Subjects may be taking an antidepressant as long as they have had a stable dose for up to 6 weeks and do not alter the dosage during the course of the study
- Men or women 40-80 years of age
- HAMD-17 scores > 14 at screen visit
- Score of 25 or greater on the Mini-Mental Status Examination
- Willing to come to MGH for screening and study participation
Exclusion Criteria:
Patients meeting any of the following criteria are to be excluded from the study:
- Subjects who, in the investigator's judgment, pose a current, serious suicidal or homicidal risk
- Patients who would not be appropriate for a delayed CBT control due to the severity of their depression based on clinical judgment as well as HAMD-17 scores > 28
- The following DSM-IV diagnoses: 1) substance use disorders, including alcohol dependence, active within the last 3 months; 2) schizophrenia; 3) delusional disorder; 4) psychotic disorders not elsewhere classified; 5) bipolar disorder; 6) MDD with psychotic features
- Subjects who meet DSM-IV criteria for dementia
- Severe, unstable concurrent medical conditions (determined by his/her physician) that are likely to require hospitalization within six months from study entry (e.g., a patient with severe congestive heart failure who has a history of recent hospital admissions)
- Subjects may not be receiving a psychosocial intervention that is specific for depression; psychosocial interventions not specific for depression (e.g., couples counseling) and established for three or more months before screen visit are allowed
Sites / Locations
- Massachusetts General Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
1
2
Arm Description
Patients randomized to the immediate arm will be given 12 weeks of CBT starting one week after randomization
Patients in the delayed arm will receive 12 weeks of CBT, starting 12 weeks after randomization.
Outcomes
Primary Outcome Measures
Response according to the Hamilton Rating Scale for Depression, 17 items (HAM-D 17).
Secondary Outcome Measures
Full Information
NCT ID
NCT00853346
First Posted
February 27, 2009
Last Updated
November 15, 2012
Sponsor
Amy Farabaugh, PhD
Collaborators
Brigham and Women's Hospital, Beth Israel Deaconess Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT00853346
Brief Title
Psychosocial Treatment of Depression in Parkinson's Disease
Official Title
Psychosocial Treatment of Depression in Parkinson's Disease
Study Type
Interventional
2. Study Status
Record Verification Date
November 2012
Overall Recruitment Status
Unknown status
Study Start Date
April 2007 (undefined)
Primary Completion Date
April 2013 (Anticipated)
Study Completion Date
April 2013 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Amy Farabaugh, PhD
Collaborators
Brigham and Women's Hospital, Beth Israel Deaconess Medical Center
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of the study is to examine the effects of a form of talk therapy called cognitive behavior therapy (CBT) in the treatment of major depression in individuals with Parkinson's disease (PD).
Detailed Description
CBT is a specific type of treatment that has been shown to be as helpful in treating depression as medications for depression. CBT focuses on thoughts, feelings, and behaviors. It focuses on the here and now, rather than the past. CBT offers concrete strategies and skills for coping with depression, PD, and other life problems. Previous research leads us to believe that this type of therapy may help people with PD cope with their depression.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Major Depressive Disorder, Parkinson's Disease
Keywords
Depression, Parkinson's Disease, Major Depression, Cognitive Behavioral Therapy
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
80 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
Patients randomized to the immediate arm will be given 12 weeks of CBT starting one week after randomization
Arm Title
2
Arm Type
Active Comparator
Arm Description
Patients in the delayed arm will receive 12 weeks of CBT, starting 12 weeks after randomization.
Intervention Type
Behavioral
Intervention Name(s)
Cognitive Behavioral Therapy
Other Intervention Name(s)
CBT, Cognitive Therapy, Therapy, Psychosocial Intervention
Intervention Description
12 weeks of Cognitive Behavioral Therapy designed for adults with Parkinson's Disease and comorbid Depression
Intervention Type
Behavioral
Intervention Name(s)
Cognitive Behavioral Therapy
Other Intervention Name(s)
CBT, Cognitive Therapy, Therapy, Psychosocial Intervention
Intervention Description
12 weeks of Cognitive Behavioral Therapy designed for adults with Parkinson's Disease and comorbid Depression
Primary Outcome Measure Information:
Title
Response according to the Hamilton Rating Scale for Depression, 17 items (HAM-D 17).
Time Frame
screen, week 4, week 8, week 12; if applicable, week 16, week 20, week 24
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
In addition to the DSM-IV diagnostic criteria for major depressive disorder, the following conditions must be met for patient eligibility:
Written informed consent.
Subjects with a primary diagnosis of PD who also currently meet DSM-IV criteria for MDD
Subjects must be stable on their anti-Parkinson treatment, as defined by no medication changes over the past 6 weeks
Subjects may be taking an antidepressant as long as they have had a stable dose for up to 6 weeks and do not alter the dosage during the course of the study
Men or women 40-80 years of age
HAMD-17 scores > 14 at screen visit
Score of 25 or greater on the Mini-Mental Status Examination
Willing to come to MGH for screening and study participation
Exclusion Criteria:
Patients meeting any of the following criteria are to be excluded from the study:
Subjects who, in the investigator's judgment, pose a current, serious suicidal or homicidal risk
Patients who would not be appropriate for a delayed CBT control due to the severity of their depression based on clinical judgment as well as HAMD-17 scores > 28
The following DSM-IV diagnoses: 1) substance use disorders, including alcohol dependence, active within the last 3 months; 2) schizophrenia; 3) delusional disorder; 4) psychotic disorders not elsewhere classified; 5) bipolar disorder; 6) MDD with psychotic features
Subjects who meet DSM-IV criteria for dementia
Severe, unstable concurrent medical conditions (determined by his/her physician) that are likely to require hospitalization within six months from study entry (e.g., a patient with severe congestive heart failure who has a history of recent hospital admissions)
Subjects may not be receiving a psychosocial intervention that is specific for depression; psychosocial interventions not specific for depression (e.g., couples counseling) and established for three or more months before screen visit are allowed
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Amy Farabaugh, PhD
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Psychosocial Treatment of Depression in Parkinson's Disease
We'll reach out to this number within 24 hrs